Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 1.84M | 5.23M | Gross Profit |
-1.11K | 0.00 | -10.05K | -6.68K | 1.82M | 5.23M | EBIT |
-5.67M | -5.73M | ― | -31.84M | -12.81M | -7.79M | EBITDA |
-4.20M | -5.57M | ― | -31.60M | -12.75M | -7.33M | Net Income Common Stockholders |
-5.57M | -5.58M | ― | -31.37M | -12.70M | -7.10M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.80M | 2.43M | 5.90M | 12.11M | 29.21M | 11.12M | Total Assets |
2.34M | 3.02M | 6.59M | 14.65M | 40.83M | 24.93M | Total Debt |
112.23K | 221.87K | 289.64K | 0.00 | 0.00 | 477.03K | Net Debt |
-1.69M | -2.21M | -5.61M | -12.11M | -29.21M | -10.64M | Total Liabilities |
2.28M | 1.51M | 1.30M | 4.27M | 2.11M | 2.77M | Stockholders Equity |
61.87K | 1.51M | 5.29M | 10.38M | 38.72M | 22.16M |
Cash Flow | Free Cash Flow | ||||
-4.35M | -4.53M | -12.85M | -19.10M | -10.20M | -10.31M | Operating Cash Flow |
-4.35M | -4.53M | -12.85M | -17.60M | -10.20M | -10.31M | Investing Cash Flow |
0.00 | 0.00 | 0.00 | -1.50M | 0.00 | -2.60K | Financing Cash Flow |
1.78M | 1.06M | 6.64M | 1.99M | 28.30M | 17.69M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
38 Underperform | $2.23M | ― | -1023.93% | ― | ― | 83.04% | |
37 Underperform | $3.51M | ― | -120.16% | ― | -7.74% | 93.25% | |
31 Underperform | $285.78K | ― | -2364.82% | ― | ― | 60.26% | |
30 Underperform | $1.64M | ― | -300.16% | ― | ― | 79.57% | |
29 Underperform | $2.58M | ― | -91.39% | ― | ― | 99.39% | |
27 Underperform | $2.80M | ― | -512.79% | ― | ― | -40.51% |
Salarius Pharmaceuticals has entered into a merger agreement with Decoy Therapeutics, resulting in a stock-for-stock transaction where Decoy stockholders will own approximately 85.9% of Salarius. The merger aims to combine Salarius and Decoy’s operations, with Decoy becoming a wholly-owned subsidiary. This merger is expected to significantly impact Salarius’ operations and industry positioning, as Decoy’s significant operations will contribute to the future of the combined company. The merger was approved by both companies’ board of directors and involves a special stockholder meeting to address various proposals related to the merger.